The Labs Your Doctor Didn't Run (Pre-Protocol Bloodwork Blueprint)

Your total testosterone number is a starting point, not an answer, and treating it like an answer is where most protocols go wrong before they even begin.

Here is the full picture of why. Testosterone is produced in the testes in response to a signal from the brain. The hypothalamus releases something called GnRH, which triggers the pituitary to release LH and FSH, which then travel to the testes and drive testosterone production. That testosterone circulates in the blood, gets bound up by proteins, converts into other hormones like estradiol, and eventually feeds back to the brain to slow the signal down. That is the whole chain. Every lab on a proper pre-protocol panel is reading a different part of that chain, and without all of them, you are flying blind.

Start with SHBG, which stands for sex hormone binding globulin and is essentially a protein that grabs testosterone in the bloodstream and makes it unavailable to your cells. A man with a total testosterone of 600 ng/dL but high SHBG can have less biologically active testosterone than a man sitting at 400 ng/dL with low SHBG, because only the unbound fraction, called free testosterone, actually gets into cells and does anything. This is not a theoretical edge case. It happens constantly, and it is the reason guys get told their labs are normal while still experiencing every symptom of low testosterone.

The harmonized reference range from a 2017 study across 9,054 men put normal total testosterone between 264 and 916 ng/dL, and that is an enormous window. Being "in range" at 270 tells you almost nothing about whether you are optimized or symptomatic or somewhere in between.

LH and FSH are the next markers that most panels skip, and skipping them removes your ability to understand the cause. LH is the signal from the pituitary telling the testes to produce testosterone. FSH drives sperm production. If testosterone is low and LH is also low, the problem is upstream, either the hypothalamus or pituitary is not sending the signal correctly, which is called secondary hypogonadism. If testosterone is low and LH is high, the testes are getting the signal and not responding to it, which is primary hypogonadism. Those two conditions look identical on a total testosterone result and require completely different treatment approaches. The Endocrine Society's 2018 clinical guidelines and the American Urological Association's 2018 guidelines both recommend measuring LH in every man with low testosterone for exactly this reason.

Estradiol and prolactin round out the hormonal picture. Estradiol is the estrogen that matters most in men and is produced primarily by the conversion of testosterone in fat tissue through a process called aromatization. Prolactin, when elevated, suppresses the entire HPG axis and is one of the first things to check if a man has low LH alongside low testosterone, because a prolactin-secreting pituitary tumor is a correctable cause that gets missed when you only run total testosterone. Accurate estradiol measurement in men requires a method called LC-MS/MS, or liquid chromatography mass spectrometry, because standard immunoassay methods are not sensitive enough to give reliable readings at male levels.

The metabolic panel extends the picture beyond hormones entirely. Fasting insulin is the key marker here, because insulin resistance typically develops silently, with blood glucose staying normal while the pancreas compensates by flooding the system with insulin to keep it there. By the time fasting glucose or hemoglobin A1c is elevated, insulin resistance has often been progressing for years. Hemoglobin A1c reflects average blood sugar over roughly three months, which makes it more informative than a single glucose reading, but insulin itself tells you the most about how hard the system is working.

Insulin resistance and low testosterone are also tightly connected. Higher body fat increases aromatase activity, which converts more testosterone to estradiol, which feeds back to suppress LH and drive testosterone lower. It runs in both directions, meaning fixing one without addressing the other tends to produce incomplete results.

On the cardiovascular side, a standard lipid panel gives you total cholesterol, LDL, HDL, and triglycerides. ApoB, or apolipoprotein B, gives you the actual particle count. Each particle of LDL carries one ApoB molecule, so ApoB tells you how many particles are circulating, not just how much cholesterol they are carrying in total. Particle number is a stronger predictor of plaque accumulation than cholesterol concentration, particularly in men with metabolic dysfunction where particles tend to be smaller and more numerous. High sensitivity C-reactive protein measures systemic inflammation and adds another layer to cardiovascular risk prediction that lipid numbers alone cannot capture.

Hematocrit is the safety marker that becomes most relevant once testosterone therapy begins. Testosterone drives red blood cell production through a mechanism involving the kidneys and something called erythropoietin. This is generally a beneficial effect at moderate levels, but when hematocrit climbs above 52 percent it starts thickening the blood in ways that increase clotting risk. A 2022 study in the Journal of Urology found that men on testosterone therapy with hematocrit at or above 52 percent had a 35 percent higher risk of major cardiovascular events and venous thromboembolism compared to men whose hematocrit stayed below that threshold. Baseline hematocrit before starting lets you know where you are beginning and gives you the reference point to track change meaningfully.

TSH, free T3, and free T4 are included because thyroid function intersects with testosterone at multiple levels. Hypothyroidism raises SHBG, which reduces free testosterone. It also produces fatigue and low libido independently, meaning a man can have genuinely normal testosterone and feel like he has low testosterone because his thyroid is underperforming. Treating testosterone when the thyroid is the actual problem is the kind of error that a complete baseline panel prevents.

IGF-1 measures the output of growth hormone activity in the body, and its main value in a pre-protocol panel is establishing a baseline before any growth hormone peptide protocol begins, so you can actually measure whether those peptides are doing anything. Without that baseline you are guessing.

The point of all of this is not to run tests for the sake of running tests. It is that every hormonal system in the body is downstream of something else and upstream of something else, and a single number pulled out of that network tells you the level but not the story. The story is where the protocol lives.

---

References

1. Bhasin S et al. Testosterone Therapy in Men With Hypogonadism. JCEM. 2018 — Endocrine Society guideline: diagnosis requires two fasting morning total T measurements, distinguish primary vs secondary via LH/FSH
2. Mulhall JP et al. Evaluation and Management of Testosterone Deficiency. AUA Guideline. J Urology. 2018 — Total T below 300 ng/dL threshold, recommend LH in all men with low T
3. Travison TG et al. Harmonized Reference Ranges for Circulating Testosterone Levels. JCEM. 2017 — 9,054 men, harmonized range 264-916 ng/dL
4. Ory J et al. Secondary Polycythemia in Men Receiving Testosterone Therapy. J Urology. 2022 — Hematocrit >=52% on TRT = 35% higher MACE/VTE risk (OR 1.35)
5. Rosner W et al. Toward Excellence in Testosterone Testing. JCEM. 2013 — Sensitive LC-MS/MS required for accurate male estradiol

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness